Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01629329 · ClinicalTrials.gov registry record · Phase 4
Prochlorperazine Versus Acetaminophen, Aspirin, and Caffeine for the Treatment of Acute Migraine
A Phase 4 study, sponsored by Albert Einstein Healthcare Network.
- Terminated
- Registry status
- Phase 4
- Development phase
- 93
- Enrollment target
NCT01629329 is a Phase 4 study that was terminated before completion, run by Albert Einstein Healthcare Network. The registered enrollment target is 93 participants.
The verdict
NCT01629329, a Phase 4 study, was terminated before completion, sponsored by Albert Einstein Healthcare Network.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 93 participants
- Enrollment target
Study Summary
The objective of this randomized, double blind study is to demonstrate that one dose oral "excedrin migraine" (acetaminophen, aspirin and caffeine) is not inferior when compared to one dose of intravenous prochlorperazine for the treatment of acute migraine headaches in the emergency department.
Interventions
- DRUG Aspirin, Acetaminophen, Caffeine pills
- DRUG Prochlorperazine 10mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2010-11 |
| Est. Completion | 2014-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01629329
The ClinicalTrials.gov registry entry for NCT01629329 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Albert Einstein Healthcare Network, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Aspirin, Acetaminophen, Caffeine pills is the first listed.
NCT01629329 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01629329 about?
NCT01629329 is a clinical study titled "Prochlorperazine Versus Acetaminophen, Aspirin, and Caffeine for the Treatment of Acute Migraine". The objective of this randomized, double blind study is to demonstrate that one dose oral "excedrin migraine" (acetaminophen, aspirin and caffeine) is not inferior when compared to one dose of intravenous prochlorperazine for the treatment of acute migraine headaches in the emergency department.
What is the current status of trial NCT01629329?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 93 participants. The study started on 2010-11. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01629329?
The interventions under investigation include: Aspirin, Acetaminophen, Caffeine pills (DRUG), Prochlorperazine 10mg (DRUG).
Who is sponsoring clinical trial NCT01629329?
This trial is sponsored by Albert Einstein Healthcare Network, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.